Veritas In Silico Inc.
| Code | Sector | Market |
|---|---|---|
| 130A | Pharmaceuticals | Growth |
| Date of listing approval | 2024/01/05 |
|---|---|
| Expected Date | 2024/02/08 |
| Lead Underwriter | Mizuho Securities Co., Ltd |
| Description |
| Listed Shares(total) | 920,000 |
|---|---|
| Trading Unit | 100 |
| New Shares | 800,000 |
| Existing Shares | 120,000¡Êonly O.A.¡Ë |
| Shares Outstanding | PreIPO 5,501,314.00 |
| PostIPO 6,301,314.00 | |
| Paid Up Capital | PreIPO Y90,000,000 |
| PostIPO Y312,548,000 | |
| Expected Pricing Date | 2024/01/23 |
| Book Building Start | 2024/01/24 |
| Book Building End | 2024/01/30 |
| Fix Date | 2024/01/31 |
| Offering Starts | 2024/02/01 |
| Offering Ends | 2024/02/06 |
| Expect Pricing | Y800-Y1,000 |
| Notional PER (based on previous period) |
-31.13--38.91 |
| Notional PER(based on results forecast) | 141.09-176.37 |
| Offering Price | Y1,000 |
| Offering Price PER (based on previous period) |
141.09-176.37 |
| Offering Price PBR (based on previous period) |
3.57 |
| Offering Price PER (based on results forecast) |
176.37 |
| Use of Funds Raised |
Financial Data
Units:Y1,000
| Fiscal Year End:2020/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 13,326 |
| Current Profit | - | -297,034 |
| Net Profit | - | -297,905 |
| Net Assets | - | 516,291 |
| Fiscal Year End:2021/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 59,330 |
| Current Profit | - | -240,082 |
| Net Profit | - | -232,319 |
| Net Assets | - | 1,683,971 |
| Fiscal Year End:2022/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 178,801 |
| Current Profit | - | -138,455 |
| Net Profit | - | -141,381 |
| Net Assets | - | 1,542,590 |
| Recent Quarter 2023/09 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 279,251 |
| Current Profit | - | 37,888 |
| Net Profit | - | 35,750 |
| Net Assets | - | 1,578,341 |
| Results Forecast 2023/12 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | 359,000 |
| Current Profit | - | 34,000 |
| Net Profit | - | 31,000 |
| Net Assets | - | - |
Per Share Units:Y1
| Fiscal Year End:2020/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - |
| Equity | -68.00 | 117.84 |
| Fiscal Year End:2021/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - |
| Equity | -51.92 | 306.10 |
| Fiscal Year End:2022/12 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - |
| Equity | -25.70 | 280.40 |
| Fiscal Year End:Recent Quarter 2023/09 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | ||
| Net Earning | - | 6.50 |
| Equity | - | - |
| Fiscal Year End:Results Forecast 2023/12 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | 5.67 |
| Equity | - | - |
Comment
| ¢£Over allotment(120,000¡Ë |
Consolidated Subsidiaries
| Name | Address |
|---|
Underwriters
| Allocation | Underwriter | Tel |
|---|---|---|
| 0% | Nomura | 03-3211-1811 |
| 93.3% | Mizuho Securities Co., Ltd | 03-5208-3210 |
| 2% | SMBC Nikko Securities Inc. | 03-5644-3111 |
| 2% | Mitsubishi UFJ Morgan Stanley Securities Co., Ltd. | 03-6213-8500 |
| 1.1% | Rakuten Securities Holdings, Inc. | 03-6406-2681 |
| 1.1% | Matsui Securities Co., Ltd | 03-5216-0606 |
| 0.5% | Akatsuki Securities,Inc | 03-5641-7800 |
Data
| Date of incorporation | 2016/11/17 |
|---|---|
| Company address | Tokyo 141-0031 |
| Telephone | 03-6421-7537 |
| President | |
| Homepage | https://www.veritasinsilico.com/ |
| Auditor | Toyo Audit |
| Major Shareholders | |
|---|---|
| Shareholder Name | Ratio |
| 86.62% | |
| 23.33% | |
| 11.96% | |
| 9.10% | |
| 8.39% | |
| 8.15% | |
| 5.63% | |
| 4.88% | |
| 4.68% | |
| 3.93% | |
| 3.40% | |
| Number of Employees | 15 as of 2023/11/30 |
|---|---|
| Birth Date of Representative | 1972/06/07 |